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TET2 is involved in a variety of hematopoietic malignancies, mainly in myeloid malignancies. Most mutations of TET2 have
been identified in myeloid disorders, but some have also recently been described in mature lymphoid neoplasms. In contrast to
the large amount of data about mutations of TET2, some data are available for gene expression. Moreover, the role of TET2 in
chronic lymphocytic leukemia (CLL) is unknown. This study analyzes both TET2 expression and mutations in 48 CLL patients.
TET2 expression was analyzed by exon arrays and quantitative real-time polymerase chain reaction (qRT-PCR). Next-generation
sequencing (NGS) technology was applied to investigate the presence of TET2 variations. Overexpression of TET2was observed in
B-cell lymphocytes from CLL patients compared with healthy donors (P = 0.004). In addition, in CLL patients, an overexpression
of TET2was also observed in the clonal B cells compared with the nontumoral cells (P = 0.002). However, no novel mutations were
observed. Therefore, overexpression of TET2 in CLL seems to be unrelated to the presence of genomic TET2 variations.
1. Introduction
The Ten-Eleven-Translocation 2 (TET2) gene encoding a 2-
oxoglutarate/Fe2+ oxygenase catalysesmainly the conversion
of methylcytosine to hydroxymethylcytosine. TET2 is impli-
cated in a variety of hematopoietic malignancies, particularly
myeloid malignancies. Mutations of TET2 have recently
been identified in 12–26% in MDS/MPN disorders [1–5],
8–19% of adult acute myeloid leukemias (AML) [6, 7]. Its
highest incidence has been found in chronicmyelomonocytic
leukemia (CMML) patients (50%) [8]. However, the presence
of somatic mutations of the TET2 gene in human mature
lymphoid neoplasms has been recently described, whereby
TET2 mutations were present in 2–12% of B-cell and 12% of
T-cell neoplasms [9–11].
In contrast to the considerable information about muta-
tions of TET2, data about expression of this gene are scarce.
TET2 showed a broad expression pattern in different tissues
in healthy donors, highlighting a 10- to 100-fold higher
expression in hematological cells, the highest values being
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seen in granulocytes. In addition, TET2 expression was lower
in the granulocytes from MDS cases compared with healthy
donors, irrespective of the TET2mutation status [3].
TET2 expression and mutations have been less studied
in chronic lymphocytic leukemia (CLL) and only rare cases
of this disease showed TET2 mutations [12]. In the present
study overexpression in CLL patients compared with healthy
donors was observed. In addition, Next-generation sequenc-
ing studies confirmed that the presence of TET2mutations is
rare in CLL.
2. Material and Methods
2.1. Patients. In total, 48 samples from CLL patients at
diagnosis and 6 healthy donors were analyzed. CLL diagnosis
was performed according to the World Health Organization
(WHO) classification [13] and Working Group of National
Cancer Institute (NCI) criteria [14]. In all cases, a complete
immunophenotypic analysis by flow cytometry [15] and FISH
studies were carried out. Main biological features of the 48
CLL patients included in the study are shown in Table 1. The
study was approved by the local ethical committees “Comite´
E´tico de Investigacio´n Cl´ınica, Hospital Universitario de
Salamanca.” Written informed consent was obtained from
each patient before they entered the study.
BothCLLB lymphocytes and normal B lymphocyteswere
purified using magnetically activated cell sorting (MACS)
CD19 MicroBeads (Miltenyi Biotec, Bergisch Gladbach, Ger-
many). CD19 selection resulted in >98% purity, as analyzed
by flow cytometry.
Genomic DNA and total RNA were obtained from clonal
B-cell lymphocytes (CD19+ cell fraction) and the remaining
cells (CD19− cell fraction). DNA was isolated by QIAgen
(Qiagen, Valencia, CA, USA), following the manufacturer’s
recommendations. RNA isolation was carried out using
TRIZOL reagent.
2.2. Expression Analysis. Genome-wide expression analysis
of the isolated samples of 27 CLL patients and 5 healthy
donors was performed using Human Exon 1.0 microarrays
(Affymetrix, Inc., SantaClara, CA,USA) following themanu-
facturer’s protocols for theGeneChip platformbyAffymetrix,
as previously reported [16]. Hybridized Affymetrix arrays
were scanned with an Affymetrix GeneChip 3 000 scanner.
Image generation and feature extraction were performed
using Affymetrix GCOS Software.
SYBR Green quantitative Real-Time PCR was done in
triplicate with SYBR Green mix (Applied Biosystems, Fos-
ter City, CA) using the IQ5 Multicolor Real-Time PCR
Detection System (Bio-Rad) in a subset of CLL patients
(𝑛 = 23) and healthy donors (𝑛 = 5) with the
following gene-specific primers: GAPDH, forward 5󸀠-CAG-
GGCTGCTTTTAACTCTGG-3󸀠 and reverse 5󸀠-GGGTGG-
AATCATATTGGAACA-3󸀠, and TET2, forward 5󸀠-GGG-
TGGAATCATATTGGAACA-3󸀠 and reverse 5󸀠-TGGACA-
CAACCACAAATTCA-3󸀠. TheGAPDH gene was used as the









































∗Some patients have more than one cytogenetic aberration.
internal control and the quantification of relative expression
(reported as arbitrary units (a.u.)) were performed using
the comparative Ct method. For analytical purposes, cut-off
values were adopted according to median-expression levels
for TET2.
2.3. Next-Generation Sequencing. NGS was carried out using
the Roche GS FLX Titanium sequencing platform to inves-
tigate the TET2 mutations in 26 CLL patients. First, Nim-
bleGen Sequence Capture was applied to sequence the entire
TET2 gene (𝑛 = 4) with a median coverage more than 20X.
Then, the 27 amplicons of the complete TET2 coding region
(𝑛 = 24) were sequenced using 454 FLX amplicon deep-
sequencing chemistry with a median coverage of 689 reads,
as previously described [17, 18]. TET2was sequenced by both
strategies in 2 patients. Moreover, the gene expression profile
of 5 out of 26 CLL patients was also analyzed by expression
arrays.
Sanger sequencing was performed in CD19-positive and
-negative cell fractions. Moreover, in 6 healthy donors a
region of exon 11 was sequenced to analyze the association
of one polymorphism in CLL. Primers used for Sanger
sequencing are shown in Table 2.
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Table 2: Sequences of primers used for Sanger sequencing.
Primer designation Sequence (5󸀠-3󸀠)
TET2 exon 3 (ENSE00002471221)
Forward GGAACACACACATGGTGAAC
Reverse TGGAACAGTCATTGTCCCTG
TET2 exon 11 (ENSE00002415078)
Forward TCCCATGAACCCTTACCCTG
Reverse ACGCTTTGCACACTCAATG
2.4. Bioinformatic Analysis. For the exon array analysis, the
robust microarray analysis (RMA) algorithm was used for
background correction, intra- and intermicroarray normal-
ization, and expression signal calculation [19]. Significance
analysis of microarray (SAM) [20] was used to calculate
significant differential expression. All bioinformatic analyses
were performed with the statistical program R, as previously
described [21].
The expression data from quantitative SYBR Green PCR
were not normally distributed, so nonparametric tests were
used. Expression levels of TET2 in the different groups were
analyzed using the Mann-Whitney test with a two-tailed
value of 𝑃 < 0.05 taken as indicating statistical significance.
All tests were performed using SPSS v19.0.
Sequencing data from the Sequence Capture experiments
were analyzed using GS Run Browser andGS ReferenceMap-
per software, version 2.0.01 (Roche Diagnostics, Mannheim,
Germany). All putative variants were compared with pub-
lished single-nucleotide polymorphism (SNP) data (dbSNP
build 130).
Amplicon deep-sequencing data were generated usingGS
FLXSequencer Instrument, version 2.3, and analyzedwithGS
Amplicon Variant Analyzer, version 2.3 (Roche Diagnostics).
The results were further processed and visualized following a
previously described pipeline [17].
3. Results and Discussion
3.1. Overexpression of TET2 in B Cells of CLL Compared with
HealthyDonors. Theexpression levels ofTET2were analyzed
in CLL patients (𝑛 = 27) and healthy donors (𝑛 = 5) using
oligonucleotide microarrays. Overexpression of the mRNA
levels of TET2 in CLL patients compared with healthy donors
was observed (𝑃 = 0.004).
These results were confirmed in 23 CLL patients and 5
healthy donors by qRT-PCR. Clonal B cells fromCLL patients
had a significantly higher expression of TET2 than B cells
from healthy donors (𝑃 = 0.033) (Figure 1(a)).
In myeloid malignancies, TET2 expression has been
shown to be lower in MDS cases than in healthy controls,
irrespective of the TET2 mutation status [3]. However, there
have been no studies addressing the expression levels ofTET2
in CLL. TET2 plays an important role in the metabolism of
5-methylcytosine to 5-hydroxymethylcytosine (5-hmC) [22].
In addition, inactivation of TET2 is related to low levels of 5-
hmC, as it has been reported in HEK293T cells [23]. In the
opposite way, TET2 overexpression could lead to an increase
of 5 hmC in CLL patients.
Moreover, TET2 overexpression in CLL was not associ-
atedwith other biologicalmarkers with well-known prognos-
tic value in CLL such as IGHV mutational status (𝑃 = 0.67)
or cytogenetic alterations (𝑃 = 0.197).
3.2. Differences in TET2 Expression in B Clonal Cells and
Normal Cells in CLL Patients. The expression differences
between the B-cell lymphocytes (CD19+) and the remaining
cells (CD19−) were studied. In healthy donors (𝑛 = 5), CD19−
cells had a higher level of TET2 expression than CD19+
cells (Figure 1(b)), consistent with the previously described
highest expression of TET2 in granulocytes [3]. As expected,
TET2 expression depends on the cell type [3]. By contrast,
overexpression was observed in the clonal CD19+ cells of
CLL patients compared with CD19− cells (𝑃 = 0.002)
(Figure 1(c)). To our knowledge, such results have not been
previously reported.
TET2 overexpression in CLL patients could be explained
by the deregulation of expression of other members of the
TET family in B cells. Compensatory action in the TET family
has also been suggested by a previous study [24]. However,
a TET2 deficient murine model has recently been proposed
in which the loss of TET2 during adult hematopoiesis is not
compensated by increased transcription of TET1 and TET3
[9].
3.3. TET2 Overexpression Is Unrelated to the Presence of
the Gene Mutations. To determine whether TET2 overex-
pression could be related to the presence of mutations or
polymorphisms in TET2, sequencing studies were carried
out. No novel variants in TET2 were revealed from the deep
sequencing study following the Sequence Capture strategy.
To further assess the presence and prevalence of TET2
mutations in CLL, the TET2 coding sequence was also ana-
lyzed in 24 CLL patients by 454 amplicon deep-sequencing.
Sequencing data of all coding exons of TET2, represented by
27 amplicons, confirmed the presence of known polymor-
phisms in TET2. However, we did not detect any mutations
that might affect the protein.
Therefore, NGS did not enable any novel and relevant
mutations in TET2 in CLL patients to be detected. Our
sequencing results are consistent with the data provided by
the International Cancer Genome Consortium and those
recently published in which the TET2 mutations were rarely
present in CLL [12, 25]. Thus, the overexpression of TET2 in
chronic lymphocytic leukemia was unrelated to the presence
of TET2mutations.
However, a large number of single nucleotide variations
described in the SNP database were detected, confirming
that the TET2 gene is a polymorphic gene. Most of these
polymorphisms were localized in exons 3 and 11 (Table 3).
Due to the primers used in NGS, three variations were also
detected in noncoding regions near the analyzed exons. One
of these polymorphisms, rs2454206, situated in exon 11, was
found in 54% (14/26) of CLL patients. To determine whether
this polymorphism could be associated with CLL, 6 healthy
donors were sequenced by Sanger. The same polymorphisms
were found in 83% (5/6) of these cases.





































































Figure 1: (a) Expression of TET2 in B cells of CLL patients compared with healthy donors (HD). Box plot of the expression levels represented
as arbitrary units (a.u.) of TET2 showing significantly different levels of expression between CLL patients (𝑛 = 23) and healthy donors (HD)
(𝑛 = 5), assessed by qRT-PCR. They indicate the overexpression of TET2 in B cells (CD19+ cells) of CLL patients compared with healthy
donors (𝑃 < 0.05). The thick line inside the box plot indicates the median expression levels and the box shows the 25th and 75th percentiles,
while the whiskers show the maximum and minimum values. Outliers are represented by open circles. (b) Expression of TET2 in CD19+ and
CD19− cells of healthy donors. It shows a tendency towards overexpression of TET2 in CD19− cells compared with CD19+ cells in healthy
donors (𝑛 = 5) (𝑃 > 0.05). (c) Expression of TET2 in CD19+ and CD19− cells of CLL patients. It illustrates the overexpression of TET2 in B
clonal cells (CD19+ cells) compared with normal cells (CD19− cells) in CLL patients (𝑛 = 15) (𝑃 < 0.05).
Recently, the correlation between the presence of poly-
morphisms in IDH1 gene and the overexpression of the gene
has been described in MDS [26]. To determine whether
the presence of TET2 polymorphisms could influence the
overexpression of this gene, the association between gene
expression and genetic data was investigated. The expression
was analyzed in the clonal CD19+ cells of CLL patients
showing polymorphisms (𝑛 = 16) and in CLL patients
without polymorphisms (𝑛 = 2). The results showed similar
TET2 expression levels in both CLL groups (data not shown).
NGS analysis of the 15 patients analyzed by qRT-PCR
showed that all but one had polymorphisms in TET2 in
both CD19+ andCD19− cells.The clonal CD19+ lymphocytes
of CLL patients showing polymorphisms (𝑛 = 14) were
also compared with corresponding CD19− cells. As expected,
the tumoral cell fraction of these cases was more strongly
expressed (𝑃 = 0.001) than the nontumoral cell fraction (data
not shown). Thus, TET2 expression could not be related to
the presence of polymorphisms and the functional effects of
harboring these polymorphisms are unclear.
In conclusion, TET2 overexpression in CLL patients
relative to healthy donors and overexpression of TET2 in B
clonal cells compared with nonclonal B cells in CLL patients
have been demonstrated. In addition, TET2 overexpression
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Table 3: Known variations of TET2 detected in 26 CLL cases by next-generation sequencing.
SNP rs Region Protein 𝑛 (%)
86C>G rs12498609 exon 3 Pro29Arg 3 (12)
100C>T rs111948941 exon 3 Leu34Phe 2 (8)
521C>A rs146031219 exon 3 Pro174His 1 (4)
652G>A rs6843141 exon 3 Val218Met 2 (8)
1088C>T rs17253672 exon 3 Pro363Leu 2 (8)
1105C>T rs150072691 exon 3 Arg369Trp 1 (4)
2599T>C rs144386291 exon 3 Tyr867His 1 (4)
5162T>G rs34402524 exon 11 Leu1721Trp 4 (15)
5167C>T rs146348065 exon 11 Pro1723Ser 1 (4)
5284A>G rs2454206 exon 11 Ile1762Val 14 (54)
5333A>G rs62621450 exon 11 His1778Arg 3 (12)
3803 + 45G>A rs17319679 Intron 7 — 2 (8)
4045 − 35C>A rs59519484 Intron 8 — 1 (4)
∗74G>A rs60786079 3󸀠UTR — 3 (12)
∗N = nucleotide N 3󸀠 of the translation stop codon.
is unrelated to the presence of the gene mutations and is
independent of the presence of polymorphisms.
The relevance of TET2 overexpression in CLL remains
unknown. Given the role of TET2 in the conversion of
methylcytosine to hydroxymethylcytosine, it could be related
to epigenetic mechanisms.
4. Conclusions
To the best of our knowledge, this is the first study about the
role of TET2 in CLL: this gene was overexpressed in clonal B
cells in CLL. However the overexpression of TET2 in CLL is
not related to TET2 variations.This report suggested that not
only loss of function but also hyperfunction ofTET2 could be
related to tumorigenesis.
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